Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8595)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Sep 27, 2018 (publication date) through Apr 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Fujisawa K, Matsumoto T, Hidaka I, Marumoto Y, Ishikawa T, Yamamoto N, Suehiro Y, Takami T, Sakaida I. Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy. World J Hepatol 2018; 10(9): 571-584 [PMID: 30310535 DOI: 10.4254/wjh.v10.i9.571] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v10/i9/571.htm |
| Number | Citing Articles |
| 1 |
Jin Li, Xiaoping Qin, Ruishan Wu, Li Wan, Liang Zhang, Rui Liu. Circular RNA circFBXO11 modulates hepatocellular carcinoma progress and oxaliplatin resistance through miR‐605/FOXO3/ABCB1 axis. Journal of Cellular and Molecular Medicine 2020; 24(9): 5152 doi: 10.1111/jcmm.15162
|
| 2 |
Hsiang-chi Tseng, Wei Xiong, Saiaditya Badeti, Yan Yang, Minh Ma, Ting Liu, Carlos A. Ramos, Gianpietro Dotti, Luke Fritzky, Jie-gen Jiang, Qing Yi, James Guarrera, Wei-Xing Zong, Chen Liu, Dongfang Liu. Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nature Communications 2020; 11(1) doi: 10.1038/s41467-020-18444-2
|
| 3 |
Qing Wu, Shunqian Wen. Multi-disciplinary treatment for hepatocellular carcinoma in primary hospitals in China during the COVID-19 epidemic. Oncology and Translational Medicine 2020; 6(5): 233 doi: 10.1007/s10330-020-0436-6
|
| 4 |
Beom-Hui Lee, Dong-Shik Lee, Chan Woo Cho, Sung-Su Yun. Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A. World Journal of Surgical Oncology 2019; 17(1) doi: 10.1186/s12957-019-1685-6
|
| 5 |
Weitao Liu, Zhi Ji, BingRui Wu, Sijing Huang, Qihang Chen, Xiaoning Chen, Yuanyan Wei, Jianhai Jiang. Siglec‐15 promotes the migration of liver cancer cells by repressing lysosomal degradation of CD44. FEBS Letters 2021; 595(17): 2290 doi: 10.1002/1873-3468.14169
|
| 6 |
Guang Cao, Xiaodong Wang, Hui Chen, Song Gao, Jianhai Guo, Peng Liu, Haifeng Xu, Liang Xu, Xu Zhu, Renjie Yang. Hepatic arterial infusion chemotherapy plus regorafenib in advanced colorectal cancer: a real-world retrospective study. BMC Gastroenterology 2022; 22(1) doi: 10.1186/s12876-022-02344-4
|
| 7 |
Su Ho Kim, Ho Jong Chun, Youdong Kim, Jung Suk Oh, Byung Gil Choi, Hae Giu Lee. Impact of aortoceliac angle in implantation of subcutaneous hepatic artery port-catheter system for hepatic arterial infusion chemotherapy via femoral approach. Acta Radiologica 2023; 64(9): 2667 doi: 10.1177/02841851231181321
|
| 8 |
Zhenwen Lin, Sheng Li, Peng Guo, Liyang Wang, Lisheng Zheng, Zixing Yan, Xi Chen, Zhuqin Cheng, Haiyi Yan, Cui Zheng, Congkuai Zhao. Columbamine suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK1/2 MAPK signaling pathways. Life Sciences 2019; 218: 197 doi: 10.1016/j.lfs.2018.12.038
|
| 9 |
Bohyun Kim, Je Hwan Won, Jinoo Kim, Yohan Kwon, Hyo Jung Cho, Jimi Huh, Jai Keun Kim. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: Radiologic and Clinical Factors Predictive of Survival. American Journal of Roentgenology 2021; 216(6): 1566 doi: 10.2214/AJR.20.23213
|
| 10 |
Gordan Adžić, Juraj Prejac, Stjepko Pleština. Long-term follow-up of complete remission in a patient with advanced hepatocellular carcinoma treated with sorafenib: a case report. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1260989
|
| 11 |
Jessica Elderkin, Najeeb Al Hallak, Asfar S. Azmi, Hussein Aoun, Jeffrey Critchfield, Miguel Tobon, Eliza W. Beal. Hepatocellular Carcinoma: Surveillance, Diagnosis, Evaluation and Management. Cancers 2023; 15(21): 5118 doi: 10.3390/cancers15215118
|
| 12 |
Wei Yuan, Wenchao Yue, Huabing Wen, Xueqin Wang, Qi Wang. Analysis on Efficacy of Hepatic Artery Infusion Chemotherapy with or without Lenvatinib for Unresectable Hepatocellular Carcinoma. European Surgical Research 2023; 64(2): 268 doi: 10.1159/000529475
|
| 13 |
Maher Hendi, Yiping Mou, Jiemin Lv, Bin Zhang, Xiujun Cai. Hepatic Arterial Infusion Chemotherapy Is a Feasible Treatment Option for Hepatocellular Carcinoma: A New Update. Gastrointestinal Tumors 2021; 8(4): 145 doi: 10.1159/000516405
|
| 14 |
Issei Saeki, Takahiro Yamasaki, Yurika Yamauchi, Taro Takami, Tomokazu Kawaoka, Shinsuke Uchikawa, Akira Hiramatsu, Hiroshi Aikata, Reo Kawano, Kazufumi Kobayashi, Takayuki Kondo, Sadahisa Ogasawara, Tetsuhiro Chiba, Kazuaki Chayama, Naoya Kato, Isao Sakaida. Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma. Cancers 2021; 13(9): 2247 doi: 10.3390/cancers13092247
|
| 15 |
Takahiro Yamasaki, Issei Saeki, Yurika Kotoh-Yamauchi, Ryo Sasaki, Norikazu Tanabe, Takashi Oono, Takashi Matsuda, Takuro Hisanaga, Toshihiko Matsumoto, Isao Hidaka, Tsuyoshi Ishikawa, Taro Takami, Yutaka Suehiro, Isao Sakaida. Clinical Benefits of Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma. Applied Sciences 2021; 11(4): 1882 doi: 10.3390/app11041882
|
| 16 |
Jincheng Wang, Rui Wu, Jin-yu Sun, Feifei Lei, Huabing Tan, Xiaojie Lu. An overview: Management of patients with advanced hepatocellular carcinoma. BioScience Trends 2022; 16(6): 405 doi: 10.5582/bst.2022.01109
|
| 17 |
Chia-Bang Chen, Chun-Min Chen, Ruo-Han Tzeng, Chen-Te Chou, Pei-Yuan Su, You-Chuen Hsu, Cheng-Da Yang. Combining HAIC and Sorafenib as a Salvage Treatment for Patients with Treatment-Failed or Advanced Hepatocellular Carcinoma: A Single-Center Experience. Journal of Clinical Medicine 2023; 12(5): 1887 doi: 10.3390/jcm12051887
|